MX2022010034A - Anticuerpos anti-il-2 diseñados. - Google Patents
Anticuerpos anti-il-2 diseñados.Info
- Publication number
- MX2022010034A MX2022010034A MX2022010034A MX2022010034A MX2022010034A MX 2022010034 A MX2022010034 A MX 2022010034A MX 2022010034 A MX2022010034 A MX 2022010034A MX 2022010034 A MX2022010034 A MX 2022010034A MX 2022010034 A MX2022010034 A MX 2022010034A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- engineered
- engineered anti
- subsets
- infection
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen en la presente anticuerpos anti-IL-2 diseñados con secuencias de aminoácidos modificadas. Los anticuerpos diseñados confieren especificidad de unión al receptor modificada a un complejo de IL-2-anticuerpo anti-IL2, inhibiendo la unión de IL-2 a CD25. Los anticuerpos anti-IL-2 diseñados facilitan la expansión de sub-conjuntos de células inmunes efectoras y disminuyen los efectos no deseables causados por la IL-2. Por tanto, los anticuerpos anti-IL-2 diseñados son útiles en el tratamiento de enfermedades tales como cáncer e infección.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977292P | 2020-02-16 | 2020-02-16 | |
| US202163139315P | 2021-01-20 | 2021-01-20 | |
| PCT/IB2021/051267 WO2021161287A2 (en) | 2020-02-16 | 2021-02-15 | Engineered anti-il-2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010034A true MX2022010034A (es) | 2022-12-13 |
Family
ID=77295172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010034A MX2022010034A (es) | 2020-02-16 | 2021-02-15 | Anticuerpos anti-il-2 diseñados. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20230085471A1 (es) |
| EP (1) | EP4103607A4 (es) |
| JP (2) | JP7292526B2 (es) |
| KR (2) | KR102627471B1 (es) |
| CN (2) | CN115397852B (es) |
| AU (2) | AU2021221287B2 (es) |
| BR (1) | BR112022016216A2 (es) |
| CA (1) | CA3166139A1 (es) |
| IL (2) | IL295210B2 (es) |
| MX (1) | MX2022010034A (es) |
| WO (1) | WO2021161287A2 (es) |
| ZA (1) | ZA202209060B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240049304A (ko) * | 2021-08-25 | 2024-04-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 융합 단백질을 함유하는 약학적 조성물 |
| CN115850471A (zh) * | 2022-10-13 | 2023-03-28 | 深圳市百士通科技开发有限公司 | 一种抗人il-2单克隆抗体及其应用 |
| CN117700554B (zh) * | 2023-08-03 | 2024-07-12 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种抗人源cd132的单克隆抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02209898A (ja) * | 1988-10-31 | 1990-08-21 | Takeda Chem Ind Ltd | 修飾インターロイキン―２ |
| WO2008070179A2 (en) * | 2006-12-06 | 2008-06-12 | Monsanto Technology, Llc | Genes and uses for plant improvement |
| WO2014100014A1 (en) | 2012-12-17 | 2014-06-26 | The Board Of Trustees Of The Leland Stanford Junior University | Super-2 complexes with antibody to augment il-2 therapy |
| NZ713641A (en) * | 2013-04-29 | 2019-08-30 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
| CA2954476C (en) * | 2014-07-10 | 2023-09-19 | Novartis Ag | Immune-stimulating monoclonal antibodies against human interleukin-2 |
| JP7497953B2 (ja) * | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| EP3428193B1 (en) | 2015-08-06 | 2020-09-30 | Agency For Science, Technology And Research | Il2rbeta/common gamma chain antibodies |
| CN108473569B (zh) * | 2016-01-11 | 2022-11-22 | 苏黎世大学 | 针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白 |
| JP2019534710A (ja) * | 2016-09-28 | 2019-12-05 | ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー | インターロイキン２に結合する抗体およびその使用 |
| CN110914297B (zh) * | 2017-05-25 | 2023-06-06 | 基础科学研究院 | 抗人白细胞介素2抗体及其用途 |
| WO2019168791A2 (en) * | 2018-02-28 | 2019-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Single-chain il-2/antibody fusions that selectively activate regulatory t cells |
-
2021
- 2021-02-15 EP EP21753736.4A patent/EP4103607A4/en active Pending
- 2021-02-15 CA CA3166139A patent/CA3166139A1/en active Pending
- 2021-02-15 BR BR112022016216A patent/BR112022016216A2/pt unknown
- 2021-02-15 AU AU2021221287A patent/AU2021221287B2/en active Active
- 2021-02-15 CN CN202180028914.7A patent/CN115397852B/zh active Active
- 2021-02-15 KR KR1020227032030A patent/KR102627471B1/ko active IP Right Grant
- 2021-02-15 IL IL295210A patent/IL295210B2/en unknown
- 2021-02-15 MX MX2022010034A patent/MX2022010034A/es unknown
- 2021-02-15 JP JP2022549329A patent/JP7292526B2/ja active Active
- 2021-02-15 CN CN202310897633.6A patent/CN117143233A/zh active Pending
- 2021-02-15 KR KR1020247001793A patent/KR20240014590A/ko active Application Filing
- 2021-02-15 US US17/795,960 patent/US20230085471A1/en active Pending
- 2021-02-15 WO PCT/IB2021/051267 patent/WO2021161287A2/en active Application Filing
- 2021-02-15 IL IL308185A patent/IL308185A/en unknown
-
2022
- 2022-08-12 ZA ZA2022/09060A patent/ZA202209060B/en unknown
- 2022-11-16 US US18/055,975 patent/US11851485B2/en active Active
-
2023
- 2023-06-06 JP JP2023092925A patent/JP2023113807A/ja active Pending
- 2023-10-23 US US18/492,028 patent/US20240092888A1/en active Pending
- 2023-11-14 AU AU2023266270A patent/AU2023266270A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240092888A1 (en) | 2024-03-21 |
| WO2021161287A3 (en) | 2021-09-16 |
| KR20220143716A (ko) | 2022-10-25 |
| ZA202209060B (en) | 2023-12-20 |
| US20230203152A1 (en) | 2023-06-29 |
| IL308185A (en) | 2024-01-01 |
| CN117143233A (zh) | 2023-12-01 |
| CA3166139A1 (en) | 2021-08-19 |
| BR112022016216A2 (pt) | 2023-02-28 |
| US11851485B2 (en) | 2023-12-26 |
| EP4103607A4 (en) | 2023-12-20 |
| IL295210B2 (en) | 2024-04-01 |
| KR102627471B1 (ko) | 2024-01-18 |
| NZ791361A (en) | 2023-08-25 |
| AU2023266270A1 (en) | 2023-12-07 |
| AU2021221287A1 (en) | 2022-08-25 |
| CN115397852A (zh) | 2022-11-25 |
| JP2023113807A (ja) | 2023-08-16 |
| KR20240014590A (ko) | 2024-02-01 |
| WO2021161287A2 (en) | 2021-08-19 |
| IL295210B1 (en) | 2023-12-01 |
| AU2021221287B2 (en) | 2023-10-05 |
| JP7292526B2 (ja) | 2023-06-16 |
| EP4103607A2 (en) | 2022-12-21 |
| CN115397852B (zh) | 2023-08-11 |
| IL295210A (en) | 2022-10-01 |
| JP2023506093A (ja) | 2023-02-14 |
| US20230085471A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202209060B (en) | Engineered anti-il-2 antibodies | |
| MX2010001090A (es) | Nuevos epitopos inmunogenicos para inmunoterapia. | |
| PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
| MX348360B (es) | Anticuerpo biespecifico psmaxcd3 de simple cadena especifico de especies cruzadas. | |
| MD3353212T2 (ro) | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora | |
| MX2022015157A (es) | Anticuerpos para tigit. | |
| EA201390847A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
| NZ595792A (en) | Antibodies specific to cadherin-17 | |
| NZ608972A (en) | Engineered nucleic acids and methods of use thereof | |
| MX2019000094A (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos. | |
| BR112022025295A2 (pt) | Células natural killer modificadas geneticamente para imunoterapia do câncer direcionada a cd70 | |
| WO2006002377A3 (en) | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates | |
| NZ610091A (en) | Antibodies | |
| MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
| MX2020007281A (es) | Composiciones y métodos que se dirigen a cánceres que expresan cd99. | |
| MX2020007338A (es) | Composiciones y métodos para el direccionamiento a tipos de cáncer que expresan clec12a. | |
| NZ602515A (en) | Proteins that bind pi16 and uses thereof | |
| CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
| PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
| DK1567018T3 (da) | Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer | |
| NO20091662L (no) | Nye antigener og antistoffer assosiert med pankreatisk, duktalt adenokarsinom | |
| ZA202305072B (en) | Cd1a antibodies and uses thereof | |
| WO2022157773A3 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| WO2024102905A3 (en) | Methods of use of anti-il-2 antibodies | |
| MX2022012050A (es) | Inmunoterapia celular para el tratamiento del cancer. |